Scarica l'app Stockscreener
61.73
2.85%
-1.81
Dopo l'orario di chiusura:
61.73
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CYTK Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$63.54
Aprire:
$63.16
Volume 24 ore:
1.88M
Relative Volume:
0.98
Capitalizzazione di mercato:
$7.55B
Reddito:
$18.47M
Utile/perdita netta:
$-589.53M
Rapporto P/E:
-11.74
EPS:
-5.26
Flusso di cassa netto:
$-399.80M
1 W Prestazione:
-2.19%
1M Prestazione:
-2.80%
6M Prestazione:
+79.66%
1 anno Prestazione:
+26.16%
Intervallo 1D:
$60.84
$63.96
Intervallo di 1 settimana:
$60.42
$64.43
Portata 52W:
$29.31
$70.98
Cytokinetics Inc Stock (CYTK) Company Profile
Nome
Cytokinetics Inc
Settore
Industria
Telefono
(650) 624-3000
Indirizzo
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Confronta CYTK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
61.73 | 7.77B | 18.47M | -589.53M | -399.80M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-18 | Aggiornamento | Goldman | Neutral → Buy |
| 2025-07-30 | Ripresa | Raymond James | Mkt Perform |
| 2025-04-24 | Iniziato | Barclays | Overweight |
| 2025-02-07 | Iniziato | Citigroup | Buy |
| 2025-01-22 | Iniziato | Stifel | Buy |
| 2024-11-08 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-08-13 | Downgrade | Goldman | Buy → Neutral |
| 2024-01-24 | Downgrade | UBS | Buy → Neutral |
| 2024-01-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | Iniziato | Goldman | Buy |
| 2023-11-07 | Iniziato | B. Riley Securities | Buy |
| 2023-08-15 | Iniziato | SVB Securities | Outperform |
| 2023-02-17 | Iniziato | BofA Securities | Neutral |
| 2022-12-23 | Reiterato | Needham | Buy |
| 2022-12-20 | Iniziato | Truist | Buy |
| 2022-10-11 | Iniziato | UBS | Buy |
| 2022-01-28 | Iniziato | Goldman | Buy |
| 2021-12-22 | Iniziato | Oppenheimer | Outperform |
| 2021-12-10 | Iniziato | JP Morgan | Overweight |
| 2021-10-07 | Iniziato | Jefferies | Buy |
| 2021-03-12 | Iniziato | Wolfe Research | Outperform |
| 2021-02-18 | Iniziato | Barclays | Overweight |
| 2021-01-20 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-29 | Iniziato | Goldman | Neutral |
| 2020-07-10 | Iniziato | Raymond James | Strong Buy |
| 2020-05-05 | Iniziato | Mizuho | Buy |
| 2020-04-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-09-10 | Ripresa | Morgan Stanley | Equal-Weight |
| 2017-11-22 | Reiterato | Morgan Stanley | Overweight |
| 2017-11-22 | Downgrade | Needham | Strong Buy → Buy |
| 2017-11-21 | Reiterato | H.C. Wainwright | Buy |
| 2017-07-31 | Iniziato | Morgan Stanley | Overweight |
| 2017-03-08 | Iniziato | Rodman & Renshaw | Buy |
| 2017-02-06 | Aggiornamento | Needham | Buy → Strong Buy |
| 2016-12-16 | Iniziato | Cantor Fitzgerald | Overweight |
| 2016-07-28 | Reiterato | Needham | Buy |
| 2015-11-10 | Reiterato | FBR Capital | Outperform |
| 2015-11-09 | Reiterato | ROTH Capital | Buy |
| 2015-07-24 | Reiterato | MLV & Co | Buy |
| 2014-12-31 | Reiterato | ROTH Capital | Buy |
| 2014-11-04 | Aggiornamento | MLV & Co | Hold → Buy |
| 2014-04-28 | Reiterato | Needham | Buy |
Mostra tutto
Cytokinetics Inc Borsa (CYTK) Ultime notizie
Cytokinetics (NASDAQ:CYTK) EVP Sells $112,590.76 in Stock - MarketBeat
Callos, Cytokinetics EVP, sells $112,584 in stock By Investing.com - Investing.com South Africa
Callos, Cytokinetics EVP, sells $112,584 in stock - Investing.com India
Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore Biomedical, ... - Bluefield Daily Telegraph
Notice to Long-Term Shareholders of Cytokinetics, Inc. - GlobeNewswire
Cytokinetics (CYTK) stock closes up 3.5% into year-end as Myqorzo launch nears, insider sale disclosed - ts2.tech
Cytokinetics, Incorporated (CYTK) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cytokinetics, Incorporated (CYTK) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Cytokinetics (CYTK) stock ends 2025 higher as Myqorzo launch nears — what’s next - ts2.tech
Moody Aldrich Partners LLC Buys Shares of 82,460 Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics Stock Soars: What’s Next? - StocksToTrade
Cytokinetics stock jumps today as CYTK traders focus on Myqorzo launch and insider filing - ts2.tech
Cytokinetics (NASDAQ:CYTK) Trading 3% HigherStill a Buy? - MarketBeat
The Year-End 2025 Biotech Rally And What It Means For 2026 - Benzinga
Top Cytokinetics Insider Just Cashed Out in a High-Profile Stock Move - TipRanks
Insider Sell: Andrew Callos Sells Shares of Cytokinetics Inc (CY - GuruFocus
Cytokinetics (NASDAQ:CYTK) EVP Andrew Callos Sells 1,809 Shares of Stock - MarketBeat
Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Molina Healthcare, Inc. ... - Bluefield Daily Telegraph
Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Molina Healthcare, Inc. (NYSE: MOH); Synopsys, Inc. (NASDAQ: SNPS); and WEBTOON Entertainment, Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf - GlobeNewswire Inc.
Notice to Long-Term Shareholders of Alexandria Real Estate - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Shareholders to Connect - ACCESS Newswire
What Does the Market Think About Cytokinetics Inc? - Benzinga
Why Is Edgewise Therapeutics Stock Soaring Wednesday? - Benzinga
Cytokinetics FY2025 EPS Forecast Reduced by HC Wainwright - MarketBeat
Squarepoint Ops LLC Has $608,000 Holdings in Cytokinetics, Incorporated $CYTK - MarketBeat
Analysts Have Conflicting Sentiments on These Healthcare Companies: Viridian Therapeutics (VRDN), Fortrea Holdings Inc. (FTRE) and Cytokinetics (CYTK) - The Globe and Mail
Insider Sell: Wendell Wierenga Sells 20,000 Shares of Cytokineti - GuruFocus
Cytokinetics (NASDAQ:CYTK) Director Sells $1,322,800.00 in Stock - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Cytokinetics Insider Sold Shares Worth $1,322,800, According to a Recent SEC Filing - marketscreener.com
Morgan Stanley Maintains Overweight Rating on CYTK, Raises PT to $71 | CYTK Stock News - GuruFocus
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Moderna (MRNA) and Disc Medicine (IRON) - The Globe and Mail
Citizens Maintains Cytokinetics (CYTK) Market Outperform Recommendation - Nasdaq
RBC Capital Maintains Cytokinetics (CYTK) Outperform Recommendation - Nasdaq
Cytokinetics: Small Label Differences With Big Commercial Stakes (CYTK) - Seeking Alpha
Cytokinetics Earnings Boost After FDA Approval - StocksToTrade
Cytokinetics’ Breakthrough: Stock Set for Big Gains? - StocksToTrade
FDA Approval Puts New Cytokinetics Heart Drug in Competition With Fast-Growing BMS Med - MedCity News
Cytokinetics (CYTK) Stock Hits 52-Week High as FDA Approval of Myqorzo Triggers Analyst Price-Target Hikes - ts2.tech
FDA says yes to Cytokinetics’ aficamten, now Myqorzo, in oHCM - BioWorld MedTech
Investors Buy Large Volume of Cytokinetics Call Options (NASDAQ:CYTK) - MarketBeat
Cytokinetics jumps after FDA approves its drug for rare heart disease - TradingView — Track All Markets
Cytokinetics Surges as FDA Grants Approval for Myqorzo - timothysykes.com
Why Is Cytokinetics Stock Soaring Monday?Cytokinetics (NASDAQ:CYTK) - Benzinga
Cytokinetics Wins FDA Approval for Cardiovascular Drug, Stock up - Finviz
UniFirst, Adeia, Cytokinetics And Other Big Stocks Moving Higher On Monday - Benzinga
Cytokinetics stock hits 52-week high at 69.46 USD - Investing.com
Cytokinetics (NASDAQ:CYTK) Hits New 52-Week High Following Analyst Upgrade - MarketBeat
RBC Capital Raises Price Target for Cytokinetics (CYTK) to $95 | CYTK Stock News - GuruFocus
Cytokinetics stock hits 52-week high at 69.46 USD By Investing.com - Investing.com Nigeria
Cytokinetics Inc Azioni (CYTK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):